Nicholas Michael Mordwinkin - Jul 24, 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Chief Business Officer
Signature
/s/ Marc Belsky, Attorney-in-Fact
Stock symbol
KZR
Transactions as of
Jul 24, 2023
Transactions value $
$0
Form type
4
Date filed
7/26/2023, 05:10 PM
Previous filing
Jan 10, 2023
Next filing
Jan 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -185K -100% 0 Jul 24, 2023 Common Stock 185K $6.84 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Award +185K 185K Jul 24, 2023 Common Stock 185K $2.28 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Award $0 +100K $0.00 100K Jul 24, 2023 Common Stock 100K $2.28 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 Twenty-five percent (25%) of the shares subject to the option shall vest on July 24, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.